Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TOP2A | P11388 | 1/20 | 0.83 |
| ▸ | KCNH2 | Q12809 | 15/20 | 0.49 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL910715 | 1.00 | TOP2A (0.83) | TOP2AKCNH2SLC2A1 | |
| Hydrochloric Acid SCHEMBL909841 | 0.99 | TOP2A (0.82) | TOP2AKCNH2SLC2A1 | |
| SCHEMBL21371945 | 0.94 | TOP2A (0.94) | TOP2AKCNH2SLC2A1 | |
| SCHEMBL3329039 | 0.94 | TOP2A (0.94) | TOP2AKCNH2SLC2A1 | |
| Hydrochloric Acid SCHEMBL3332892 | 0.93 | TOP2A (0.93) | TOP2AKCNH2SLC2A1 | |
| Gepotidacin SCHEMBL29379990 | 0.91 | TOP2A (1.00) | TOP2AKCNH2SLC2A1 | |
| Gepotidacin SCHEMBL3332319 | 0.91 | TOP2A (1.00) | TOP2AKCNH2SLC2A1 | |
| Gepotidacin SCHEMBL17536702 | 0.91 | TOP2A (1.00) | TOP2AKCNH2SLC2A1 | |
| SCHEMBL909984 | 0.90 | TOP2A (0.68) | TOP2AKCNH2SLC2A1 | |
| Gepotidacin SCHEMBL17515232 | 0.90 | TOP2A (0.98) | TOP2AKCNH2SLC2A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2238138-A1 | TRICYCLIC NITROGEN COMPOUNDS AND THEIR USE AS ANTIBACTERIAL AGENTS | Glaxo Group Limited (GB) | 2010-10-13 | — | — | EP | claimed |
| WO-2009087153-A1 | TRICYCLIC NITROGEN COMPOUNDS AND THEIR USE AS ANTIBACTERIAL AGENTS | GLAXO GROUP LIMITED (GB) | 2009-07-16 | — | — | WO | claimed |